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Introduction: Targeting the CD20 antigen has been a successful therapeutic intervention in the treatment of
rheumatoid arthritis (RA). However, in some patients with an inadequate response to anti-CD20 therapy, a persistence
of CD20- plasmablasts is noted. The strong expression of CD319 on CD20- plasmablast and plasma cell populations in
RA synovium led to the investigation of the potential of CD319 as a therapeutic target.
Methods: PDL241, a novel humanized IgG1 monoclonal antibody (mAb) to CD319, was generated and examined for its
ability to inhibit immunoglobulin production from plasmablasts and plasma cells generated from peripheral blood
mononuclear cells (PBMC) in the presence and absence of RA synovial fibroblasts (RA-SF). The in vivo activity of PDL241 was
determined in a human PBMC transfer into NOD scid IL-2 gamma chain knockout (NSG) mouse model. Finally, the ability
of PDL241 to ameliorate experimental arthritis was evaluated in a collagen-induced arthritis (CIA) model in rhesus monkeys.
Results: PDL241 bound to plasmablasts and plasma cells but not naïve B cells. Consistent with the binding profile,
PDL241 inhibited the production of IgM from in vitro PBMC cultures by the depletion of CD319+ plasmablasts and
plasma cells but not B cells. The activity of PDL241 was dependent on an intact Fc portion of the IgG1 and mediated
predominantly by natural killer cells. Inhibition of IgM production was also observed in the human PBMC transfer to
NSG mouse model. Treatment of rhesus monkeys in a CIA model with PDL241 led to a significant inhibition of
anti-collagen IgG and IgM antibodies. A beneficial effect on joint related parameters, including bone remodeling,
histopathology, and joint swelling was also observed.
Conclusions: The activity of PDL241 in both in vitro and in vivo models highlights the potential of CD319 as a
therapeutic target in RA.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
marked by chronic pain and joint damage characterized by
synovial inflammation and hyperplasia. The pathology of
RA is complex, with many different cell subsets playing a
role in the disease initiation and progression [1]. One of the
defining features of the disease is the presence of auto-
antibodies in the serum, including rheumatoid factor (RF)
and antibodies directed against cyclic citrullinated peptide* Correspondence: hakju.kwon@abbvie.com
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reproduction in any medium, provided the or[2]. Disease modifying anti-rheumatic drugs (DMARDs) in-
clude those targeting the underlying immune processes that
drive the pathology, including small molecule immunosup-
pressive agents and biologics. The most widely prescribed
biologic agents are blockers of the TNF-α pathway. Patients
who become refractory to anti-TNF therapy may be treated
with agents that target the IL-6 pathway (tocilizumab, bind-
ing the IL-6 receptor), prevent T cell costimulation (abata-
cept, which binds CD80 and CD86 [3]) or deplete B cells
from the circulation (anti-CD20 mAb rituximab [4]). The
production of auto-antibodies by cells of the B cell lineage
prompted the investigation of anti-B cell therapies for treat-
ment of RA [5]. However, B cell depletion has also beend. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stimulate T cell proliferation, produce cytokines and assist
in the development of lymphoid tissue architecture [6].
Despite the tremendous progress in the treatment of RA, a
substantial group of RA patients have inadequate responses
to current therapies or have safety issues. The presence of
late stage plasmablasts as a marker of resistance in active
RA patients non-responsive to anti-CD20 therapy [7] illus-
trates the need for therapies targeted against plasmablasts
and plasma cells. CD20 is not typically expressed by im-
munoglobulin (Ig)-producing plasmablasts [8]. To this end,
we attempted to identify new targets for development of
RA therapeutics that target plasmablasts. Previous studies
have demonstrated the expression of the cell surface glyco-
protein CD319 on plasma cells [9], which became the focus
of the current study.
CD319 (SLAMF7, CS1, 19A24, novel Ly9, CRACC) is
a 66 kDa glycoprotein member of the SLAM superfam-
ily [10]. Members of the SLAM superfamily share a
common structure consisting of a membrane proximal
C-type Ig fold and a membrane distal V-type Ig fold.
The cytoplasmic region of CD319 contains two immu-
noreceptor tyrosine-based switch motifs (ITSM), which
bind to SH2-only adapter molecules Src homology 2 do-
main protein 1A/SLAM-associated protein (SAP) and
EWS-activated transcript-2 (EAT-2) [11,12]. Phosphor-
ylation of the tyrosine motifs leads to activation of
downstream molecules including PLCγ1, PLCγ2 and
PI3K kinases and modification of a variety of cell func-
tions. As observed with other SLAM family members,
CD319 engages in homophilic interactions which may
potentiate cell activation [13]. Interestingly in the ab-
sence of EAT, CD319-CD319 interactions may exert a
negative regulatory effect on natural killer (NK) cells
[14]. Two CD319 transcripts have been identified in hu-
man NK cells, with a shorter form of CD319 (CD319-S)
postulated to have a separate function from the longer
form (CD319-L) due to its lack of ITSMs [15].
Expression of CD319 is restricted to cells of hema-
topoietic origin including plasma cells, resting NK cells, a
subset of CD8+ T cells and plasmacytoid dendritic cells
(DC), with minimal expression on resting B cells, resting
CD4+ T cells and monocytes [9]. Upregulation of CD319
expression has been observed following activation of B
cells, CD4+ T cells, monocyte-derived DC and monocytes
[16] suggesting that CD319 may play a role in immune
regulation. In support of this hypothesis, high CD319 ex-
pression has been observed on plasma cells or B cells from
several disease indications including systemic lupus ery-
thematosus [17], and the transformed cells in multiple
myeloma [16] indicating the potential for CD319 as a
therapeutic target for plasmablast and/or plasma cell-
driven diseases. In this study, we investigated the expres-
sion of CD319 in RA tissues, and generated PDL241, ahumanized monoclonal antibody (mAb), to target cells ex-
pressing CD319. CD319 was expressed on plasma cells in
RA synovial tissues. PDL241 inhibited the production of
immunoglobulins in an Fc-dependent manner in vitro by
killing plasmablasts and plasma cells. Finally, PDL241 was
tested for activity in a human-severe combined immuno-
deficiency (hu-SCID) mouse model of Ig production and a
rhesus macaque model of collagen-induced arthritis
(CIA). The data demonstrate the potential of CD319 as a
therapeutic target in RA.
Methods
Immunohistochemistry analysis
Synovial tissues were obtained from 26 individuals with
RA according to the approved protocol (PDL-011-04RA)
reviewed by the Mayo Clinic Institutional Review Board.
All patients gave their written informed consent after the
risks and benefits of the study were explained. The 1G9
mAb, which recognizes an intracellular epitope of CD319
[9], was used to stain formalin fixed paraffin embedded
(FFPE) tissues using an automated immunostainer (Dako
North America, Carpinteria, CA, USA) with 3,3′-diamino-
benzidine detection (Ventana Medical Systems, Tucson,
AZ, USA). Double labeling studies were performed using
1G9 in combination with an anti-CD3, anti-CD20, anti-
CD56 (LabVision, Fremont, CA, USA), anti-CD68 (Dako)
and anti-CD138 (Invitrogen, Camarillo, CA, USA). VS38c
mAb (Dako) was also used as a plasma cell marker.
PDL241 was used to stain optimal cutting temperature
(OCT) embedded frozen tissues from human or rhesus
monkeys for immunohistochemistry (IHC) and im-
munofluorescence studies. AF488-conjugated streptavi-
din (Invitrogen) was used to detect PDL241 staining
after prior incubation with biotinylated donkey anti-
human Ab (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA). AF555 or AF594- conjugated anti-
mouse or rabbit secondary Ab (Invitrogen) were used to
detect other cell surface markers in a co-staining study.
Slides were counter-stained with 4′,6-diamidino-2-pheny-
lindole (DAPI) to visualize cell nuclei.
Generation of PDL241
Female BALB/c mice (Taconic, Hudson, NY, USA) were
immunized with purified CD319 protein and mAb were
generated by fusing spleen cells to the NS0 fusion partner
(American Type Culture Collection). Anti-CD319 specific
mAb were identified using a variety of selection techniques
including ELISA for CD319 protein, immunoblotting and
flow cytometry analysis of CD319-expressing and CD319
non-expressing cell lines. The mouse parental mAb of
PDL241 (m241) was selected for its ability to bind to
CD319 protein from human and non-human primates
(NHP). M241, a mouse IgG1, was chimerized to human
IgG1 for initial functional characterization prior to
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the method of Queen et al. [18] and resulted in PDL241,
which was engineered onto an IgG1 κ backbone with
T250Q and M428L mutations in the Fc domain designed to
extend the in vivo half-life via an enhanced binding to FcRn
[19]. A FcR-binding deficient mutant of PDL241 (241-
G2M3) was made by fusing the PDL241 variable domains
to human IgG2M3 Fc domains [20]. F(ab)’2 fragments were
produced by pepsin cleavage and purification on protein A.
The negative control IgG1 mAb (cIgG1) for PDL241 used
throughout this study was MSL109, a fully human anti-
cytomegalovirus mAb [21]. Material for in vivo studies was
produced in NS0 cells. All materials were tested for endo-
toxin (<0.02 EU/mg) and protein aggregation (<1%).
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were ob-
tained from the heparinized blood of normal volunteer do-
nors (AbbVie Biotherapeutics or Stanford Blood Center,
Palo Alto, CA, USA) by separation on 50 ml Leucosep™
tubes (Greiner Bio-one N.A. Inc., Monroe, NC, USA) or
Ficoll-Paque Plus (GE Healthcare Lifesciences, Piscataway,
NJ, USA). After two rounds of washes with PBS, PBMC
were resuspended at 1 × 106 cells/ml in R-10 media
(Roswell Park Memorial Institute (RPMI) containing 10%
heat inactivated FBS, 1X Pen/Strep, 20 mM HEPES).
Cell staining and flow cytometry
To determine the phenotype of cells that were bound by
PDL241, 2 × 106 PBMC collected from healthy individuals
were labeled for analysis of lymphocytes, while 1 × 106
PBMC were used for analysis of plasma cells and dendritic
cells. After the addition of Fc block (Miltenyi, Auburn,
CA, USA), PBMC were incubated at 4°C for 30 minutes
with fluorochrome-conjugated antibodies specific for cell
surface markers CD3 (SK7 and SP34-2), CD4 (RPA-T4),
CD8 (RPA-T8), CD56 (MY31), CD16 (3G8), CD14
(M5E2), CD19 (SJ25C1), CD27 (M-T271), CD38 (HB7),
CD11c (B-ly6), CD123 (7G3), HLA-DR (L243), and
lineage cocktail 1 (lin 1) (BD Bioscience, San Jose, CA,
USA) and CD138 (B-B4, Miltenyi) with AF488 labeled
PDL241. Cells were washed twice with PBS and then ana-
lyzed on a BD FACSCanto.novi Luc90 (AbbVie Biothera-
peutics) is an anti-CD319 mAb that does not compete for
CD319 binding with PDL241.
Pokeweed mitogen-induced IgM production assay
PBMC (2 × 105 in 200 μl) were treated with cIgG1 or
PDL241 in the presence of 0.25 μg/ml pokeweed mitogen
(PWM) (Sigma, St. Louis, MO, USA) in 96-well round bot-
tom plates. At day 7, supernatants were harvested and the
level of secreted IgM was measured using an Easy-Titer
IgM assay kit (ICL Inc., Portland, OR, USA) according to
the manufacturer’s instructions. In some experiments, NKcells or monocytes were depleted from PBMC by positive
selection using RoboSep® (STEMCELL Technologies,
Vancouver, BC, Canada) according to the manufacturer’s
instructions.
Cell depletion experiments
PBMC (4 × 105 in 200 μl) were treated with cIgG1,
PDL241 or rituximab in 96-well round bottom plates. Fol-
lowing six days of culture at 37°C, cells were harvested
and the absolute count of each PBMC subset was deter-
mined by flow cytometry. PBMC were incubated at 4°C
for 20 minutes with fluorochrome-conjugated antibodies
(CD3, CD19 and CD27) in 100 μl PBS after the addition
of Fc blocker. Cells were washed once with PBS and resus-
pended in 130 μl PBS containing 30 μl of counting beads.
Samples were then analyzed with a BD FACSCanto and
absolute cell counts were calculated using the following
equation:
number of cell events
number of bead events
 assigned bead count of the lot beads=30μlð Þ
volume of sample μlð Þ
¼ concentration cells=μlð Þ
% live cells were calculated as % of absolute cell num-
ber of test mAb over cIgG1.
Co-cultures of RA-synoviofibroblasts with PBMC
RA- synovial fibroblasts (SF) were purchased from Cell
Applications, Inc (San Diego, CA, USA), and routinely
maintained in synoviocyte growth medium (Cell Appli-
cations) at 37°C, 5% CO2. RA-SF (passage number >5)
were seeded into 24-well plates at 6 × 104 cells per well
and allowed to reach confluence for 24 hours. PBMC
(6 × 105/well) were added to the confluent monolayers
of RA-SF. The co-cultures were then treated with mAb
(10 μg/ml) for seven days. At the end of the culture
period, PBMC (suspension and adherent) were har-
vested by extensive washing followed by trypsin-
ethylenediaminetetraacetic acid (EDTA). PBMC were
washed once with fluorescence-activated cell sorting
(FACS) buffer (PBS + 2% FBS), and subjected to FACS
staining in FACS buffer containing cIgG1 or Luc90-
FITC and IgD-PE; and CD38-PEcy7, CD27-APC, and
CD19-APCcy7.
HuSCID model of IgM production
Human PBMC (2 × 107) were injected into the peritoneal
cavity of six to eight week old NSG mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJmice, The Jackson Laboratory,
Bar Harbor, ME, USA) in 200 μl of PBS. For histological
examination of human leukocyte cell surface markers,
mice were sacrificed 14 days post PBMC transfer to assess
the cell viability and the expression of CD319 on human T
cells, B cells, NK cells and plasma cells in the spleens. Sec-
tions (5 μm) were cut from OCT-embedded frozen spleens
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Plasma was obtained from blood samples by centrifuga-
tion, and stored at −20°C until the time of analysis. Human
IgM levels were measured as described above. These stud-
ies were performed in compliance with the U.S. Depart-
ment of Health and Human Services Guide for the Care
and Use of Laboratory Animals under a PDL Biopharma/
Facet Biotech IACUC-reviewed and approved protocol.
CpG-driven IgM production in rhesus monkey PBMC
Rhesus PBMCs were isolated by Ficoll gradient separation
from freshly drawn rhesus blood (California National
Primate Research Center (Davis, CA, USA)). Cells were
cultured in 96-well plates in R-10 medium. The TLR-9
agonist CpG-B DNA prototype ODN2006 was obtained
from HyCult Biotech (Plymouth Meeting, PA, USA), and
added to cultures at a concentration of 2.5 ug/ml. Cells
were cultured for thirteen days, and the IgM levels in cul-
ture supernatants were determined by ELISA.
Rhesus monkey collagen-induced arthritis study
In accordance with the Dutch law on animal experimenta-
tion, the study protocol and experimental procedures were
reviewed and approved by the Experimental Animal Care
and Use Committee of the Biomedical Primate Research
Centre (BPRC) before the experiments started. Animals
were purchased from the Animal Science Department of
the BPRC in Rijswijk, The Netherlands. CIA-susceptible
monkeys were seronegative for the dominant class I major
histocompatibility complex resistance marker Mamu-B26
[22,23]. The total study group comprised of 24 young
adult, healthy rhesus monkeys (Macaca mulatta). During
the study the monkeys were housed socially, where pos-
sible, in cages specifically designed to house NHP. The ani-
mals were offered a daily diet consisting of monkey food
pellets (Hope Farms, Woerden, The Netherlands), fresh
fruit and vegetables and bread. Drinking water was avail-
able ad libitum. Analgesic medication (Buprecare®, 0.3 mg/
ml buprenorfine base; Schering-Plough B.V., Maarssen,
The Netherlands) was given based on the assessment of
the animal caretakers and BPRC’s veterinary staff (start and
dosing increased or stopped on the basis of behavioral
changes). The ulcerative skin lesions developing at the
immunization sites were treated with wound spray (Ace-
derm; Intervet, Boxmeer, The Netherlands) each time that
an animal was sedated, in order to prevent infection. The
study protocol was reviewed and approved by the BPRC
Experimental Animal Care and Use Committee.
For induction of CIA, chicken type II collagen (chCII)
was dissolved in 0.1 M acetic acid to a final concentration
of 10 mg/ml and mixed with an equal volume of complete
Freund’s adjuvant (CFA; DIFCO, Detroit, MI, USA). CIA
was induced by injection of 1.0 ml emulsion (5 mg chCII/
animal) into the dorsal skin distributed over 10 spots of100 μl (one time only). Clinical signs were recorded by daily
cage-side monitoring of behavioral changes (apathy, loss of
appetite) or pain (avoidance of limb usage). Monkeys were
sedated by intramuscular injection of 0.1 ml/kg of ketamine
(10 mg/ml) for determination of bodyweight (an accepted
surrogate disease marker for the CIA model), body
temperature, blood collection and a physical inspection of
the limbs for redness and/or swelling of the joints twice
weekly. For the clinical and ethical management of the
monkeys, observations were recorded using the integrated
discomfort scoring scheme previously described [24-26].
To determine the efficacy of PDL241, groups were
treated with either vehicle, PDL241 (30 mg/kg) or PDL241
(100 mg/kg). Eight animals per group ensured sufficient
statistical power. The evaluation period was 70 days. Dos-
ing solutions were given as a bolus infusion on days 7, 21
and 35. A planned fourth infusion on day 49 was cancelled
due to the development of systemic infusion reactions in
eight drug-treated animals (one death) shortly after the
third infusion. We hypothesized that this infusion reaction
was caused by the development of anti-drug antibodies
(ADA) around day 35; therefore, a decision was made to
cancel the fourth infusion. ADA were confirmed at the end
of study using an ELISA-based method.
Overall clinical score, a composite score ranging from 0
to 5, was the primary endpoint. Serum C-reactive protein
(CRP) levels, body weight loss, soft-tissue swelling (STS)
count, serum levels of collagen-specific IgG and IgM, urin-
ary excretion of collagen breakdown products hydroxyly-
sylpyridinoline (HP) and lysylpyridinoline (LP) (biomarker
of bone remodeling), histopathology and time to sacrifice
were secondary endpoints. Following immunization, all
monkeys developed an acute phase response (serum CRP
level >50 mg/L after induction of arthritis), indicating that
100% of all animals showed characteristics of an ongoing
severe inflammatory process. Urinary excretion of the col-
lagen crosslinks HP and LP was determined twice weekly,
starting from the day of CIA induction, as previously de-
scribed [24,27]. The levels of HP and LP were normalized
to creatinine levels (nmol levels per mmol creatinine) to
compensate for a possible dilution by spilled drinking
water. Blood markers of CIA were examined. Blood for
hematology and for serum chemistry was collected once
a week; CRP analysis was performed twice a week. All
hematological and clinical chemistry analyses were per-
formed at the Laboratory for Clinical Chemistry (BPRC)
on a Sysmex Sf-3000 (Goffin Meyvis, The Netherlands)
and a COBAS INTEGRA-400+ (Roche, Almere, The
Netherlands), respectively. Serum samples were col-
lected twice weekly for analyses of rhesus anti-chCII
antibody levels of the IgM and IgG isotype as described
elsewhere [28].
Histological parameters of the joint were examined. One
proximal (PIP) and one distal interphalangeal (DIP) joint
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toes with outward signs of inflammation; two fingers/toes
with no visible signs of inflammation) were processed at
the BPRC for histopathological examination for synovitis
and/or bone/cartilage destruction. After fixation in 4%
phosphate-buffered formalin, the bones were decalcified for
at least three weeks in Kristensen’s solution (17% formic
acid in 1M NaOH, pH 2.2). Decalcified bones were washed
in tap water for 16 hours, dehydrated in ethanol/toluene,
and embedded in paraffin. Sections of 2 μm thickness were
cut and stained with hematoxilin/eosin. Histopathology was
analyzed and graded by a pathologist blinded to the study.
Histopathology was scored based on a histopathology grad-
ing system published by Pettit et al. [29]. This system quan-
tifies the degree of inflammation, cartilage damage and
bone damage on an arbitrary scale from 0 to 5.
Statistical analysis
Due to the development of neutralizing ADA prior to day
35, followed by the subsequent loss of drug exposure, the
data analysis was limited to the period from day 0 to day 31
post induction. Late responders to CIA induction (CRP
levels >100 mg/l after day 21) may have experienced a lim-
ited effect of the treatment because of the previously de-
scribed development of neutralizing antibodies. Analysis
was, therefore, performed on ‘all animals’ (n = 8/group) and
on those animals that responded early to the induction
(CRP levels >100 mg/l on or before day 21; ‘early CRP on-
set group’; Placebo group n = 5; 30 mg/kg group n = 5;
100 mg/kg group n = 7). Statistical analyses were conducted
using Prism 5 software (GraphPad Software, Inc. La Jolla,
CA, USA). Statistical differences comparing the placebo-
treated group at each time point with either treated group
(30 mg/kg or 100 mg/kg) were determined using a two-A B
D E
Figure 1 CD319 is expressed on RA synovial tissue (IHC) and is a mar
were used for IHC analysis of CD319 using (A) 1G9 alone and co-stained w
studies were performed using 1G9 in combination with (B) anti-CD3 (T cel
(macrophages), and (F) CD138 for plasma cells. Brown staining represented
staining cells are purple. FFPE, formalin fixed paraffin embedded; IHC, immtailed unpaired t test. Results with P <0.05 (*) or P <0.01
(**) were considered to be statistically significant.
Results
Expression of CD319 in RA synovium
To identify the immune cell subsets that co-express CD319
in RA synovium, FFPE synovial tissues from 26 RA subjects
were stained with a mAb to CD319 (clone 1G9) and vari-
ous hematopoietic cell markers. Expression of CD319 was
restricted to infiltrating leukocytes (Figure 1A), with few
cells double stained for CD319 and markers of T cells
(CD3, Figure 1B), B cells (CD20, Figure 1C), NK cells
(CD56, Figure 1D), or macrophages (CD68, Figure 1E).
Figure 1E was taken from a portion of the tissue different
than the other markers to obtain a clear visualization of the
macrophages. The cells that were CD319+ were predomin-
antly CD138+ plasma cells (Figure 1F). The expression pat-
tern of CD319 in RA tissues, therefore, was different from
that of the CD20 antigen recognized by rituximab, and pro-
vided the opportunity to directly target plasma cells.
PDL241 binding to leukocytes
The restricted expression of CD319 on RA synovium
plasma cells prompted the generation of PDL241, a novel
humanized mAb to CD319, as described in the Methods
section. As there is disparate literature on the binding of
anti-CD319 mAb to leukocytes, especially the binding to
the B lymphocyte lineage [9,11,30-33], an extensive analysis
of the binding of PDL241 to various leukocyte subsets from
human blood was performed. PDL241 bound to the major-
ity of NK cells, a subset of CD8+ T cells, a minor sub-
population of CD4+ T cells, and plasmacytoid and myeloid
DC but not naïve B cells, memory B cells, resting mono-
cytes or granulocytes (Figure 2A). Binding of PDL241 to BC
F
ker of plasma cells. FFPE samples of synovial tissues from RA patients
ith cell surface markers for leukocyte subsets (B-F). Double labeling
ls), (C) anti-CD20 (B cells), (D) anti-CD56 (NK cells), (E) anti-CD68
CD319 reactivity while other cell surface markers stained red. Double
unohistochemistry; RA, rheumatoid arthritis.
AB
Figure 2 Binding of PDL241 to leukocytes. (A) PBMC subsets
were labeled for immunofluorescence analysis on the basis of
co-staining: CD3+ CD4+ and CD3 + CD8+ (T cells); CD3-CD56+
(NK cells) and CD3 + CD56+ (NKT cells); CD19+ (B cells) and CD14+
(monocytes); CD27 + CD38 + CD138+ (plasmablasts and plasma
cells). Lineage negative cells were first gated and then separated
into HLA-DR + CD11c + (mDC), HLA-DR + CD123+ (pDC) and
HLA-DR-CD123+ (basophils). Data representative of 1 of 10 donors.
(B) Immunofluorescence analysis of co-staining of PDL241 (green)
with anti-CD3 (T cells), anti-CD20 (B cells) or VS38c Ab (plasma cells)
in red on OCT embedded frozen tissues from normal human tonsil.
Nuclei were counter-stained with DAPI (blue). Double stained cells
appeared yellow. Ab, antibody; DAPI, 4′,6-diamidino-2-phenylindole;
NK, natural killer; OCT, optimal cutting temperature; PBMC, peripheral
blood mononuclear cells.
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plasma cells (described below). In addition, the binding of
PDL241 on sections of normal human tonsil (a rich source
of B lymphocytes that express a variety of phenotypes and
activation states) was examined, and confirmed that
PDL241 bound to VS38c+ plasma cells (Figure 2B).Fc-dependent inhibition of Ig production by PDL241
The leukocyte subset binding pattern of PDL241 prompted
the examination of the effect of the mAb in assays of B cell
function. As PDL241 bound to terminally differentiated B
cells, the activity of the mAb on the production of Ig by
PWM-stimulated PBMC was examined. PDL241 was engi-
neered with a human IgG1 Fc domain, and as a conse-
quence, IgM was measured in the Ig production assays to
limit interference from the humanized mAb. In time-
course studies, a single high concentration (10 μg/ml) of
PDL241 inhibited IgM measured in the supernatants of
PBMC cultures seven days and nine days after initiation of
the cultures (Figure 3A). The inhibition of PWM-induced
IgM production by PDL241 was dependent on both the
concentration of mAb and the presence of an intact Fc re-
gion, as PDL241 F(ab’)2 did not inhibit IgM production
(Figure 3B). The ability of intact PDL241 but not F(ab’)2
PDL241 to inhibit IgM production was suggestive of a role
for Fc receptors in the activity of PDL241. To identify an
FcR-bearing cell subset responsible for mediating the activ-
ity of PDL241, NK cells or monocytes were depleted from
PBMC by positive selection prior to the addition of
PDL241. Depletion of NK cells but not monocytes greatly
reduced the activity of PDL241 (Figure 3C). To determine
if PDL241 inhibited Ig production by actively depleting B
cells or plasma cells, the total number of live plasmablasts,
B cells and T cells were determined after culture of PBMC
with CpG and PDL241. In contrast to rituximab and con-
sistent with the binding pattern of PDL241 to various B cell
subsets, PDL241 had no effect on B cell counts (Figure 3D).
However, both PDL241 and rituximab significantly reduced
the number of plasmablasts. PDL241 and rituximab had no
effect on T cell counts in these cultures. The activity of ri-
tuximab was likely due to the removal of resting B cells,
which were therefore unable to differentiate into plasma-
blasts as CD20 is not expressed on plasmablasts and
plasma cells [8]. To confirm the specificity of PDL241 for
late stage, differentiated plasmablasts, PBMC were cultured
for six days and the expression of CD319 on the CD27
+CD38+ plasmablasts was measured. These cells were uni-
formly high for CD319 expression (Figure 3E). Addition of
PDL241 to the cultures resulted in the disappearance of the
CD319hiCD27+CD38+ cells. The data indicated that
PDL241 mediated its inhibitory effect on IgM production
by depleting CD319+ plasmablasts in an Fc-FcR-dependent
manner.
PBMC-RA synovial fibroblast co-culture
Given the strong expression of CD319 in leukocyte infil-
trates in RA synovial tissue and the inhibitory activity of
PDL241 on Ig production, the ability of PDL241 in modu-
lating inflammatory cellular reactions within an RA lesion
was modeled using a PBMC-RA synovial fibroblast








































































































































Figure 3 (See legend on next page.)
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Figure 3 PDL241 inhibits Ig production from PBMC by specifically depleting plasmablasts and plasma cells. (A) Time course of inhibition
of IgM production from PBMC. Representative of n = 2 experiments. (B) Inhibition of IgM by PDL241 is dependent on mAb concentration and
intact mAb, as F(ab’)2 fragments of PDL241 showed no activity. The dose dependent inhibition of IgM by PDL241 was demonstrated in >10
donors; F(ab’)2 experiment was a representative experiment of two. (C) Depletion of NK cells but not monocytes from PBMC reduces the
inhibitory activity of PDL241. Representative experiment of n = 4; P = 0.01 for NK cell depleted compared to PBMC. (D) PDL241 treatment results
in specific reduction in plasmablast counts in PBMC cultures. In contrast to rituximab (open bars), PDL241 treatment (closed bars) of PBMC
specifically depleted plasma cells but not B cells from PBMC cultures. Counts were expressed as% of cIgG1-treated cultures. Data represent the
mean and SD of n = 6 experiments from distinct donors. P ≤0.001 for B cell depletion by rituxan compared to PDL241 at 1 and 10 μg/ml.
(E) CD319 was highly expressed on plasmablasts in PBMC cultures, (left panel, black histogram). Dot plots showing CD27 + CD38+ plasmablasts
following treatment with cIgG1 control (middle panel) or PDL241 (right panel). Ig, immunoglobulin; mAB, monoclonal antibody; NK, natural killer;
PBMC, peripheral blood mononuclear cells; SD, standard deviation.
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ing factors by RASF-activated B cells led to an increase in
CD27+CD38+ plasmablasts/plasma cells. Consistent with
the data described above, CD27+CD38+CD138+ plasma
cells were positive for CD319, whereas CD27+CD38-
memory B cells and CD27-CD38+ naïve B cells were
CD319- (Figure 4A). Addition of PDL241 to the PBMC-
RASF co-cultures specifically depleted the plasma cells,
whereas rituximab depleted all B cell populations
(Figure 4B). As rituximab does not bind to CD20- plasma
cells, it is likely that the effect of rituximab in these assays
was due to depletion of cells prior to differentiation to
plasma cells. An Fc-binding deficient mutant of PDL241
(241-G2M3) had no effect on cell depletion, confirming
























Figure 4 PDL241 treatment of RA synovial fibroblast-PBMC co-culture
(A) B cells differentiated into CD19+CD27hiCD38hiCD319+ plasmablasts afte
were cultured with RA synovial fibroblasts. At day 0 and day 7, cells in the
days, differentiated plasmablast cells (CD19+CD27hiCD38hi) (gate 1) could b
compared to isotype control staining (dotted line); in contrast, memory (CD
express CD319. (B) Removal of CD319+ plasmablast cells by PDL241 in RA
specifically depleted CD19+CD27hiCD38hi plasmablasts, as compared to ritu
PDL241 (241-G2M3) had no effect on plasmablast cell numbers. The numb
recoded. A representative experiment of n = 4 is shown. PBMC, peripheral bCD319 expression and activity of PDL241 in HuSCID mice
To investigate the effect of PDL241 in an in vivo model,
NSG mice were reconstituted with human PBMC and
treated with PDL241. In preliminary experiments to verify
human PBMC reconstitution, spleens of mice that had
been transfused with human PBMC were harvested
14 days after initial cell injection for expression analysis.
CD319 expression on human leukocytes in the spleens
was confirmed by staining with human specific mAb 1G9.
Double staining of 1G9 (green) and cell surface markers
(red) was used to confirm CD319 expression on the
engrafted human leukocytes. Cells of human origin were
detected by staining for human CD45. Many human
CD45+ leukocytes expressed CD319 (Figure 5A). Consist-





s leads to reduction on plasmablasts with no effect on B cells.
r co-culture with RA-synovial fibroblasts. PBMC from normal donors
culture were analyzed by flow cytometry. After co-culture for seven
e detected and were found to be CD319 positive (solid line) as
19+CD27+) (gate 2) and naïve B cells (CD19+CD27−) (gate 3) did not
synovial fibroblast-PBMC co-cultures. Addition of PDL241 to cultures
ximab, which depleted only B cells. A FcR-binding deficient mutant of
er in the gated population was calculated based on 10,000 events






















Figure 5 PDL241 binds human leukocytes and inhibits human Ig production in huSCID mice. NSG mice were transfused with human
PBMC. (A) Double staining of CD319 (green fluorescence) and human leukocyte cell surface markers as indicated (red fluorescence) in the spleen.
Cells expressing both markers were co-stained and appear yellow. 600X magnification. (B) Mice were sorted into groups on day 10
post-transfusion, and dosed twice weekly with PDL241 or cIgG1. IgM levels in the serum were measured at day 32 and day 47. In this experiment,
PDL241 treatment resulted in significant reduction of human IgM compared to cIgG1 (day 32 P = 0.003 and day 47 P = 0.004 two tailed t-test).
Significant reduction in IgM was observed in 6 of 11 separate experiments. huSCID, human-severe combined immunodeficiency; Ig,
immunoglobulin; PBMC, peripheral blood mononuclear cells.
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plasma cells in the mouse spleens were double stained in-
dicating CD319 expression (yellow, Figure 5A). In con-
trast, very few CD3+ T cells or CD20+ B cells expressed
CD319.
The presence of both human NK cells and CD319-
expressing plasma cells provided the rationale to test the
activity of PDL241 on human IgM production in this
model. Detectable levels of human IgM on day 14 in the
mouse sera ranged from 0 to 100 μg/ml, and treatment
groups were block randomized from mice with serum con-
centrations of human IgM >10 μg/ml. Experiments in
which a majority of mice had <10 μg/ml human IgM on
day14 were terminated. Treatment groups were analyzed
for the serum levels of human IgM post-treatment twice at
approximately two week intervals. An example of a study
showing significant activity of PDL241 on reducing human
IgM levels is shown (Figure 5B). PDL241 significantly re-
duced the IgM levels in Hu-SCID sera in 6 of 11 experi-
ments. The reason for the experiment-to-experimentvariation in PDL241 activity is unclear, but may reflect the
health of human FcR positive cells in the engrafted mice.
Evaluation of PDL241 activity on biomarkers of CIA in
rhesus monkeys
Since binding of PDL241 is restricted to human and non-
human primate CD319 and does not bind to CD319 from
rodent species, including mouse and rat (data not shown),
the effect of treatment with PDL241 could not be evalu-
ated in rodent models of arthritis. Therefore, a NHP
model of arthritis (collagen-induced arthritis, CIA) was
utilized. Disease symptoms in the rhesus monkey CIA
model are critically dependent on anti-collagen type II
(CII) immunoglobulins [22,25]. Given the effects of
PDL241 on Ig production in vitro and in NSG mice, the
hypothesis that PDL241 would reduce the severity of arth-
ritic disease by inhibiting antibody production against CII
was tested.
To ascertain that the CD319 expression pattern in rhesus
monkeys was similar to that in humans, PDL241 was used
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http://arthritis-research.com/content/15/6/R207to stain frozen sections from rhesus lymph node. PDL241
bound to VS38c+ plasma cells in rhesus monkey lymph
node and tonsil, but not to CD20+ B cells (Figure 6A). In
addition, CD319 was over-expressed in draining lymph
nodes from rhesus monkeys that had been immunized
with type II collagen and developed arthritic disease
(Figure 6B). Functional analysis demonstrated that PDL241
was able to inhibit ODN2006-induced IgM production
from rhesus PBMC, albeit with approximately 10 fold
lower potency than for human PBMC (Figure 6C). This



























Figure 6 PDL241 binds to plasma cells in rhesus monkey. (A)
Immunofluorescence co-staining of PDL241 and anti-CD20 or VS38c in
tonsils from normal rhesus monkey. PDL241 staining was green, CD20
and VS38c stained red and nuclei were counter-stained with DAPI (blue).
Cells with double staining (PDL241 and VS38c) appeared yellow. (B) IHC
staining of PDL241 to draining lymph nodes from normal (N) or collagen
immunized (CIA) rhesus monkey. (C). PDL241 but not Fc mutant
241-G2M3 inhibited IgM production from rhesus monkey PBMC
stimulated with the TLR-9 agonist ODN2006. CIA, collagen-induced
arthritis; DAPI, 4′,6-diamidino-2-phenylindole; IgM, immunoglobulin M;
IHC, immunohistochemistry; PBMC, peripheral blood mononuclear cells.showing that the binding affinity of PDL241 to rhesus
CD319 was 10 to 20 fold lower than to human CD319. As
observed in human PBMC cultures, the activity of PDL241
was dependent on Fc-FcR interactions as the FcR-binding
deficient mAb 241-G2M3 had no activity in these assays.
A separate pharmacokinetics/pharmacodynamics (PK/PD)
study in rhesus monkeys designed to identify the optimal
dosing strategy to ensure sufficient occupancy of CD319 on
peripheral lymphocytes by PDL241 over the 70 day study
was conducted prior to the efficacy study in the CIA model.
Simulation modeling suggested that a regimen of 30 mg/kg
every two weeks (q2w) for a total of four doses would main-
tain a saturating serum concentration of PDL241 for 70 days.
A high dose (100 mg/kg) group was included in order to
maximize the pharmacological activity of PDL241. This dose
was selected as the maximum amount of drug that could be
infused based on the formulation. No major toxicities had
been observed at this dose level in a separate non-GLP mul-
tiple dose-range finding study in cynomolgus monkeys (data
not shown). A group of 24 healthy rhesus monkeys (male/
female) were immunized with chicken type II collagen
(chCII) emulsified in CFA. All 24 animals developed an
acute phase response (CRP >50 mg/L after day 7) character-
istic of an ongoing severe inflammatory process during the
course of the study. In this model, the association between
early onset of CRP in immunized monkeys with the rapid
loss of body weight (and, therefore, a more rapid and severe
form of the disease), has been established [26]. We also ob-
served the development of a strong ADA response in the
majority of monkeys treated with PDL241 (data not shown).
ADA responses are common in NHP treated with human-
ized mAb due to the xenogenic nature of the human im-
munoglobulin. The consequence of ADA in this study was
reduced exposure of the mAb, which decreased the ability
of PDL241 at the doses administered to be effective at later
time points (data not shown). To this end, efficacy data in
this study were analyzed from all animals and in a subset of
animals with early onset of CRP based on the time the
serum CRP reached 100 mg/L after immunization (‘early
CRP onset’). The subgroup analysis allowed the comparison
of treatment versus placebo groups in monkeys that had a
more rapid onset and severe disease while removing those
monkeys with later disease onset from the analysis.
Treatment with PDL241 at 30 or 100 mg/kg had no or a
minimal (not statistically significant) effect on all clinical
parameters tested in analyses of all animals (Figure 7) or
the early CRP onset subgroup (not shown). These parame-
ters included bodyweight loss (Figure 7A), clinical score,
(Figure 7B), increase in serum CRP (Figure 7C), onset of
clinical symptoms (Figure 7D) and overall survival time
(Figure 7E). Despite the lack of statistically significant ac-
tivity on the clinical endpoints, a detailed investigation
into the sub-clinical, joint-related, inflammatory responses
was undertaken. The analysis of the early CRP onset






















































































Figure 7 PDL241 had no effect on clinical parameters in the rhesus monkey CIA model. The analysis of all animals showed no effect of
PDL241 on (A) bodyweight loss relative to day 0; (B) average clinical score; and (C) serum CRP levels. PDL241 treatment had no effect on
(D) disease free survival or (E) overall survival. CIA, collagen-induced arthritis; CRP, C-reactive protein.
Woo et al. Arthritis Research & Therapy 2013, 15:R207 Page 11 of 15
http://arthritis-research.com/content/15/6/R207subgroup (but not the all animals group) showed activity
of PDL241 in alleviating these joint-related endpoints in
the subgroup of monkeys with an early CRP onset. A
dose-dependent decrease in the production of chCII spe-
cific IgM and IgG antibodies was observed in the ‘early
CRP onset’ group (Figure 8A and B). The overall clinical
score does not take into account the number of joints that
are affected (joints with soft tissues swelling) and the se-
verity of swelling for each individual joint. These parame-
ters are summarized in the Small Joint Swelling Score
(SJS, the sum of the severity of swelling for all arthritic
small joints). A dose-dependent reduction in SJS was ob-
served in the ‘early CRP onset’ groups treated with PDL
241 compared to the placebo treated group which attained
statistical significance in the ‘early CRP onset’ animals
treated with 100 mg/kg (Figure 8C). Along with an effect
on anti-collagen antibodies and the SJS score, a decrease
in damage to cartilage and bone in the early CRP onset
group was inferred by the reduction in the collagen break-
down products HP (Figure 8D) and to a lesser extent with
LP (Figure 8E) measured in the urine.
The effect of the treatment was also analyzed at the level
of histopathology. In total, eight joints/animal (four PIPs
and four DIPs; one finger/extremity) were analyzed
for histopathology. Analysis of both the ‘all animals’
(Figure 9A) and the ‘early CRP onset’ subgroup (Figure 9B)
showed a dose dependent reduction in inflammation,cartilage damage and bone damage that was highly signifi-
cant for animals treated with 100 mg/kg.
Discussion
The treatment paradigm for RA has changed significantly
with the advent of biologic therapies, including inhibitors
of TNF-α, costimulation blockade, CD20-mediated B cell
depletion and modulation of the IL-6 pathway [35]. How-
ever, there remains a need to identify safe and effective
treatments for patients refractory or intolerant to the
current standard of care. In the current study, CD319 was
identified as a potential therapeutic target using IHC ana-
lysis of RA synovial tissue, where the molecule was
expressed at high levels on CD20 negative plasmablasts and
plasma cells. The further differentiation of CD319 from
CD20-targeted therapies was observed using PDL241, a
novel humanized IgG1 mAb. PDL241 inhibited Ig produc-
tion from PBMC in vitro by specifically depleting plas-
mablasts and plasma cells that expressed high levels of
surface CD319, via antibody-dependent cellular cytotoxicity
(ADCC). The activity of PDL241 in a rhesus monkey model
of CIA provided further support as to the therapeutic po-
tential of anti-CD319 therapy in RA. An anti-CD319 ap-
proach may provide particular benefit to patients who are
refractory to anti-CD20 therapy with the presence of late
stage plasmablasts in their disease tissue [7]. It is expected




























































































Figure 8 PDL241 treatment reduced the severity of
joint-related disease parameters in a rhesus CIA model.
Analyses are provided for ‘all animals’ and animals with ‘early CRP
onset’ as described in the Methods section. Collagen type II-specific
IgM (A) and IgG (B) were measured by ELISA. (C) The small joint
swelling score is a representation of the number of joints affected
(joints with soft tissues swelling) and the severity of swelling for
each individual joint. Urinary excretion of the collagen crosslinks
(D) hydroxylysylpyrridinoline (HP) and (E) lysylpyrridinoline (LP) was
determined, with the levels normalized to creatinine levels
(nmol levels per mmol creatinine) to compensate for a possible
dilution by spilled drinking water. Pl = Placebo, 30 = 30 mg/kg and
100 = 100 mg/kg. * P ≤0.05; ** P ≤0.01. CIA, collagen-induced
arthritis; CRP, C-reactive protein; Ig, immunoglobulin.
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plasma cells by PDL241. However, as B cells are thought
to have a broader role in the autoimmune process, includ-
ing antigen presentation, assisting in the development of
lymphoid tissue architecture within the joint, and produc-
tion of inflammatory cytokines [6], further investigation of
CD319 biology in the RA disease process is warranted.
The mechanism of action of PDL241 is similar to that of
another anti-CD319 mAb, elotuzumab. Elotuzumab has
shown potent activity in vitro and in vivo against multiple
myeloma cell lines and primary multiple myeloma cells,
with the activity in both settings being attributed to ADCC.
Neither PDL241 nor elotuzumab mediate complement
dependent cytotoxicity or direct cytotoxic activity [36].
PDL241 binds a different epitope on CD319 than elotuzu-
mab, with the PDL241 epitope residing on the membrane
distal V domain, whereas elotuzumab binds the proximal
C2-Ig domain. These mAb have differential effects on
CD319 function. Elotuzumab enhances the homotypic ad-
hesion of CD319, whereas PDL241 inhibits this interaction
(Collins et. al., submitted). The role of CD319 as an ADCC
target may come from its polarized expression in uropods
[16]. Along with the ability to associate in a homotypic man-
ner, CD319 has also been postulated to be involved in the
interaction of multiple myeloma cells with bone marrow
stroma [16]. The counter-receptor for CD319 on bone mar-
row stromal cells has not been defined, but is likely distinct
from CD319, which has expression restricted to hematopoietic
cells [9]. Although the function of CD319 on plasma cells is
not known, it is possible that it plays a role in the bone mar-
row niches for plasma cell survival. Likewise, a role for CD319
in mediating interactions of leukocytes with the stroma in the
inflamed synovium has not been investigated.
PDL241 showed promising activity in the rhesus monkey
CIA model. The development of clinical arthritis in the CIA
model is dependent on the production of CII specific IgM
[28]. Mamu-B 26-ve rhesus monkeys of Indian origin develop
clinical arthritis and show a good production of CII specific
IgM. Mamu-B 26+ve rhesus monkeys are resistant to the de-










































































































































Figure 9 PDL241 treatment reduced the severity of joint-related histopathological parameters in the rhesus CIA model. The
histopathology score was based on a grading system described by Petit et al. [29]. Analyses were performed for (A) ‘all animal’ or (B) the ‘early
CRP onset’ subgroup. CIA, collagen-induced arthritis; CRP, C-reactive protein.
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of IgM is prominently associated with early responders to
induction. The activity of PDL241 on anti-collagen anti-
bodies observed in the model was consistent with the ability
of the mAb to inhibit IgM production by PBMC in vitro. Al-
though effects were detected on other disease-related pa-
rameters, there was a minimal effect on overall clinical
scores, in part due to the severe inflammatory response in
this model. Due to the labor-intensive nature of this model
and only limited experience with other biologic drugs that
are in the public domain [26], it was not possible to bench-
mark currently approved therapeutics in the current study.
The in vivo study was hampered by the immunogenicity
of PDL241 in this rhesus monkey model, resulting in the
development of ADA leading to strong infusion reactions
following the third infusion. Retrospective analysis con-
firmed the presence of high levels of neutralizing ADA in
serum collected on day 35 before the third infusion, and
moderate to high levels of IL-6 and TNF-α were detected
in serum collected shortly after infusion. A 90% reduction
in complement levels (as determined by the CH50 assay)
was also observed in post-dose serum samples (data not
shown). As the reaction was observed at later time points
and not associated with the initial dose of PDL241, it is
likely that the infusion reactions were mediated by immu-
nocomplexes of ADA and PDL241. A similar response to
PDL241 was observed in a multiple dose GLP toxicology
study, performed in parallel to this study in cynomolgus
monkeys as part of the preclinical development of PDL241.
Although ADA to human immunoglobulins in NHP
are relatively common and not predictive of clinical im-
munogenicity [37], the magnitude of the response toPDL241 has prevented further development of this anti-
body. It is unclear if the strong immunogenicity of PDL241
was due to highly immunogenic amino acid sequences or
the biology of the PDL241-CD319 interaction. The expres-
sion of CD319 on APC [11,38] may lead to enhanced pres-
entation of humanized mAb leading to an enhanced ADA
response. In support of this hypothesis, we have found that
PDL241 was substantially more immunogenic in a
huCD319 transgenic B57BL/6 mouse than in a wild-type
B57BL/6 mouse (unpublished data). The association of
CD319 with EAT-2 may also play a role in the enhanced
immunogenicity of PDL241 [39].
Literature on the expression of CD319 on naïve B cells is
not consistent, with studies showing no expression
[9,11,33] and expression [30-32] on B cells prior to their
activation and/or differentiation. PDL241 did not bind
naïve B cells and did not deplete B cells in culture. There
was no difference in the binding of PDL241 to the long or
the short forms of CD319 when expressed on 293 cells
(data not shown). The mAb used in IHC studies showed
binding mainly to plasma cells in tissues with limited stain-
ing of other cell subsets (the current study, and [9]). As the
sensitivity of IHC is lower than flow cytometry, the more
limited expression pattern of CD319 in tissue was more
likely a consequence of sensitivity rather than a reflection
of different biology in tissues versus blood. The expression
of CD319 on other leukocytes provides the potential for
other mechanisms of action aside from the depletion of
plasmablasts and plasma cells. CD319 expression has been
reported on subsets of T cells, notably a subset of CD8+ T
cells and activated CD4+ T cells, the majority of NK and
NK T cells, DC and activated monocytes [9,11]. Binding of
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file of CD319. The ability of PDL241 to inhibit T cell func-
tion was not examined in this study; however, preliminary
data support an inhibitory activity on T cell proliferation
via depletion of CD319-expressing T cells. The expression
of CD319 on pDC and mDC [38] may provide further
therapeutic opportunities for anti-CD319 mAb. Although
development of PDL241 was halted due to the immuno-
genicity concerns described above, our data highlight the
potential of CD319 as a therapeutic target in a range of
autoimmune diseases where CD319-expressing cells have a
role in the pathology.
Conclusions
The expression of CD319 in RA synovium led to the inves-
tigation of the potential of CD319 as a target in RA.
PDL241, a novel humanized mAb to CD319, demonstrated
activity in vitro against plasmablasts/plasma cells and in a
NHP model of RA. Our data highlight the therapeutic po-
tential of targeting CD319, which may be especially relevant
in anti-CD20 therapy non-responsive disease associated
with the presence of plasmablasts.
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